The issues with Ventavia, if true, are not something typical or expected at all. And it is even less expected that any reported issues will not be followed up by the regulator. While it is true that many trials suffer from similar issues, it is not the standard that we should accept.

And I don't understand why so many think that BJM article tries to cast doubt on the entirety of Pfizer's vaccine operation? It is nothing like that at all. It clearly says the issue is with one research organization contracted by Pfizer. Maybe it is because you lack the context and jump to quick conclusions?